169 related articles for article (PubMed ID: 11836564)
1. Infrequent mutations of the activating transcription factor-2 gene in human lung cancer, neuroblastoma and breast cancer.
Woo IS; Kohno T; Inoue K; Ishii S; Yokota J
Int J Oncol; 2002 Mar; 20(3):527-31. PubMed ID: 11836564
[TBL] [Abstract][Full Text] [Related]
2. Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors.
Medina PP; Carretero J; Fraga MF; Esteller M; Sidransky D; Sanchez-Cespedes M
Genes Chromosomes Cancer; 2004 Oct; 41(2):170-7. PubMed ID: 15287030
[TBL] [Abstract][Full Text] [Related]
3. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.
Dallol A; Da Silva NF; Viacava P; Minna JD; Bieche I; Maher ER; Latif F
Cancer Res; 2002 Oct; 62(20):5874-80. PubMed ID: 12384551
[TBL] [Abstract][Full Text] [Related]
4. The human mammary-derived growth inhibitor (MDGI) gene: genomic structure and mutation analysis in human breast tumors.
Phelan CM; Larsson C; Baird S; Futreal PA; Ruttledge MH; Morgan K; Tonin P; Hung H; Korneluk RG; Pollak MN; Narod SA
Genomics; 1996 May; 34(1):63-8. PubMed ID: 8661024
[TBL] [Abstract][Full Text] [Related]
5. Mutations and deletions of the CBP gene in human lung cancer.
Kishimoto M; Kohno T; Okudela K; Otsuka A; Sasaki H; Tanabe C; Sakiyama T; Hirama C; Kitabayashi I; Minna JD; Takenoshita S; Yokota J
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):512-9. PubMed ID: 15701835
[TBL] [Abstract][Full Text] [Related]
6. Identification of a 428-kb homozygously deleted region disrupting the SEZ6L gene at 22q12.1 in a lung cancer cell line.
Nishioka M; Kohno T; Takahashi M; Niki T; Yamada T; Sone S; Yokota J
Oncogene; 2000 Dec; 19(54):6251-60. PubMed ID: 11175339
[TBL] [Abstract][Full Text] [Related]
7. Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion.
Shigemitsu K; Sekido Y; Usami N; Mori S; Sato M; Horio Y; Hasegawa Y; Bader SA; Gazdar AF; Minna JD; Hida T; Yoshioka H; Imaizumi M; Ueda Y; Takahashi M; Shimokata K
Oncogene; 2001 Jul; 20(31):4249-57. PubMed ID: 11464291
[TBL] [Abstract][Full Text] [Related]
8. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions.
Cairns P; Okami K; King P; Bonacum J; Ahrendt S; Wu L; Mao L; Jen J; Sidransky D
Cancer Res; 1997 Dec; 57(23):5356-9. PubMed ID: 9393760
[TBL] [Abstract][Full Text] [Related]
9. Defining a common region of deletion at 13q21 in human cancers.
Chen C; Brabham WW; Stultz BG; Frierson HF; Barrett JC; Sawyers CL; Isaacs JT; Dong JT
Genes Chromosomes Cancer; 2001 Aug; 31(4):333-44. PubMed ID: 11433524
[TBL] [Abstract][Full Text] [Related]
10. Absence of p51 alteration in human ovarian cancer.
Shinozaki H; Okamoto A; Shimizu K; Saito M; Yokota J; Ochiai K
Int J Oncol; 2001 Mar; 18(3):549-52. PubMed ID: 11179485
[TBL] [Abstract][Full Text] [Related]
11. Absence of p53 gene mutations in primary neuroblastomas.
Vogan K; Bernstein M; Leclerc JM; Brisson L; Brossard J; Brodeur GM; Pelletier J; Gros P
Cancer Res; 1993 Nov; 53(21):5269-73. PubMed ID: 8221661
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism of transcriptional repression of gelsolin in human breast cancer cells.
Dong Y; Asch HL; Ying A; Asch BB
Exp Cell Res; 2002 Jun; 276(2):328-36. PubMed ID: 12027462
[TBL] [Abstract][Full Text] [Related]
13. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer.
Sekido Y; Pass HI; Bader S; Mew DJ; Christman MF; Gazdar AF; Minna JD
Cancer Res; 1995 Mar; 55(6):1227-31. PubMed ID: 7882313
[TBL] [Abstract][Full Text] [Related]
14. Genomic structure of the human tetratricopeptide repeat-containing gene, TTC4, from chromosome region 1p31 and mutation analysis in breast cancers.
Su G; Casey G; Cowell JK
Int J Mol Med; 2000 Feb; 5(2):197-200. PubMed ID: 10639601
[TBL] [Abstract][Full Text] [Related]
15. The 3p21 candidate tumor suppressor gene BAF180 is normally expressed in human lung cancer.
Sekine I; Sato M; Sunaga N; Toyooka S; Peyton M; Parsons R; Wang W; Gazdar AF; Minna JD
Oncogene; 2005 Apr; 24(16):2735-8. PubMed ID: 15735765
[TBL] [Abstract][Full Text] [Related]
16. Reduced transcription of the RB2/p130 gene in human lung cancer.
Xue Jun H; Gemma A; Hosoya Y; Matsuda K; Nara M; Hosomi Y; Okano T; Kurimoto F; Seike M; Takenaka K; Yoshimura A; Toyota M; Kudoh S
Mol Carcinog; 2003 Nov; 38(3):124-9. PubMed ID: 14587097
[TBL] [Abstract][Full Text] [Related]
17. LRP-DIT, a putative endocytic receptor gene, is frequently inactivated in non-small cell lung cancer cell lines.
Liu CX; Musco S; Lisitsina NM; Forgacs E; Minna JD; Lisitsyn NA
Cancer Res; 2000 Apr; 60(7):1961-7. PubMed ID: 10766186
[TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosity affecting the APC and MCC genetic loci in patients with primary breast carcinomas.
Medeiros AC; Nagai MA; Neto MM; Brentani RR
Cancer Epidemiol Biomarkers Prev; 1994 Jun; 3(4):331-3. PubMed ID: 8061582
[TBL] [Abstract][Full Text] [Related]
19. Homozygous deletion at chromosome 2q33 in human small-cell lung carcinoma identified by arbitrarily primed PCR genomic fingerprinting.
Kohno T; Morishita K; Takano H; Shapiro DN; Yokota J
Oncogene; 1994 Jan; 9(1):103-8. PubMed ID: 7905618
[TBL] [Abstract][Full Text] [Related]
20. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer.
Gao WM; Romkes M; Day RD; Siegfried JM; Luketich JD; Mady HH; Melhem MF; Keohavong P
Carcinogenesis; 2003 Oct; 24(10):1671-6. PubMed ID: 12844488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
